Pharmacyclics LLC, a subsidiary of AbbVie, is a leading biopharmaceutical company headquartered in the United States. Founded in 1991, the company has made significant strides in the oncology sector, focusing on the development of innovative therapies for blood cancers. With a strong presence in major operational regions across North America and Europe, Pharmacyclics is renowned for its flagship product, ibrutinib, a groundbreaking treatment for various types of leukaemia and lymphoma. The company has achieved notable milestones, including rapid advancements in clinical trials and regulatory approvals, solidifying its position as a key player in the oncology market. Pharmacyclics is committed to improving patient outcomes through its unique, targeted therapies, which have transformed the treatment landscape for haematological malignancies. With a focus on research and development, Pharmacyclics continues to lead the way in delivering effective solutions for patients worldwide.
We don't have data for Pharmacyclics LLC, but we can show you information about their parent organization instead.
View parent company